Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
 SummaryQuotesChartsNewsRatingsCompanyFinancials 
Estimated financial data (e) (USD)
Sales 2019 4 991 M - -
Net income 2019 2 404 M - -
Net Debt 2019 74,6 M - -
P/E ratio 2019 10,1x
Yield 2019 -
Sales 2020 6 070 M - -
Net income 2020 603 M - -
Net cash position 2020 68,0 M - -
P/E ratio 2020 57,4x
Yield 2020 -
Capitalization 40 336 M 40 336 M -
EV / Sales 2019 4,81x
EV / Sales 2020 5,62x
Nbr of Employees 3 837
Free-Float 91,0%
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The CompanyÔÇÖs marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The CompanyÔÇÖs clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Alexion Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
B-
More Ratings
All news about ALEXION PHARMACEUTICALS, INC.
08/30ASTRAZENECA : to Mandate COVID-19 Shots for US Staff
MT
08/28ALEXION PHARMACEUTICALS : FCA Remits Pricing Decision On ALEXION'S SOLIRIS To PMPRB
AQ
08/26ASTRAZENECA : Rare Disease Drug Improves Copper Mobilization in Late-Stage Study
MT
08/23ALEXION PHARMACEUTICALS : Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotroph..
AQ
08/20FTSE : Consumer staples, financials lift FTSE 100 after worst week since February
RE
08/20ASTRAZENECA : Unit Alexion Discontinues Late-Stage Trial of ALS Drug Candidate Due to Lack..
MT
08/20FTSE 100 Falls as Growth Fears Persist; More Volatility Possible
DJ
08/20AstraZeneca's antibody therapy prevents COVID-19, study shows
RE
08/20Alexion Discontinues CHAMPION-ALS
CI
08/20ASTRAZENECA : Alexion to Discontinue Ultomiris Phase 3 ALS Trial
DJ
08/06ALEXION PHARMACEUTICALS : Canadian Drug Price Review Board Reined In
AQ
08/05"THIS COURT DOES NOT SIGN BLANK CHEQ : Federal Court Of Appeal Reverses Canada's Patented ..
AQ
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - executive
RE
07/29London Indexes Boosted by Positive Welcome to Most Earnings
DJ
07/29ASTRAZENECA : First-Half Revenue Soars on New Medicines, COVID-19 Vaccine Boost
MT
More news
News in other languages on ALEXION PHARMACEUTICALS, INC.
08/30AstraZeneca va rendre obligatoires les injections de COVID-19 pour le personnel américa..
08/20Aktien Europa Schluss: Freundlicher Wochenausklang dank US-Rückenwind
08/20Aktien Europa: Anleger bleiben vorsichtig
08/20ASTRAZENECA : fin d'un essai non concluant sur la SLA
08/20Astrazeneca mit Covid-19-Antikörper erfolgreich - weitere Arznei floppt
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Income Statement Evolution
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors